Entera Bio Ltd.
Entera Bio Ltd. (ENTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ENTX · as of Sep 30, 2025
Ownership Breakdown
22
Institutional Holders
▲ 3 vs Q2
$17.65M
Total Inst. Value
▼ $1.75M vs Q2
49.29M
Shares Outstanding
freeFloat 80.21%
9.19M
13F Shares Held
▼ 1.02M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ENTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
KNOLL CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.88M | 12.56% | 12.56% | $11.29B | Nov 14, 2025 | — held |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.18M | 2.52% | 2.52% | $2.26B | Nov 14, 2025 | ▼ 1.52M |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 627.3K | 1.34% | 1.34% | $1.20B | Nov 13, 2025 | NEW |
SCHONFELD STRATEGIC ADVISORS LLC biological products, (no diagnostic substances) | 567.0K | 1.21% | 1.21% | $1.09B | Nov 14, 2025 | ▼ 37.6K |
PARKMAN HEALTHCARE PARTNERS LLC biological products, (no diagnostic substances) | 280.8K | 59.96% | 59.96% | $539.18M | Nov 14, 2025 | ▼ 75.0K |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 148.7K | 31.74% | 31.74% | $285.44M | Nov 14, 2025 | ▼ 52.1K |
BESSEMER GROUP INC biological products, (no diagnostic substances) | 140.8K | 30.07% | 30.07% | $270.00M | Nov 5, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 88.4K | 18.87% | 18.87% | $169.73M | Nov 13, 2025 | ▲ 24.1K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 67.2K | 14.34% | 14.34% | $128.98M | Nov 14, 2025 | ▲ 18.3K |
SIGNATURE ESTATE & INVESTMENT ADVISORS LLC biological products, (no diagnostic substances) | 47.3K | 10.10% | 10.10% | $90.87M | Nov 5, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
6
Increased
+105.7K shares3
New Positions
first time holders7
Decreased
−1.74M shares1
Sold Out
fully exitedNet shares change (top 50)
1.63M
+105.7K / −1.74M
Net new holders
+1
3 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ENTX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Galitzer Hillel Chief Operating Officer | May 7, 2026 | Award | 72,993 | — | — | 163.6K | Form 4 ↗ |
Yaacov-Garbeli Dana Chief Financial Officer | May 7, 2026 | Award | 58,394 | — | — | 171.4K | Form 4 ↗ |
Burshtein Gregory Chief of R&D | May 7, 2026 | Award | 87,591 | — | — | 189.0K | Form 4 ↗ |
Germano Geno J director | Mar 9, 2026 | Purchase | 20,000 | $1.30 | $26.0K | 40.0K | Form 4 ↗ |
Ellis Sean director | Mar 5, 2026 | Purchase | 10,000 | $1.23 | $12.3K | 188.1K | Form 4 ↗ |
Taitel Haya director | Feb 10, 2026 | Purchase | 7,500 | $1.48 | $11.1K | 0 | Form 4 ↗ |
Germano Geno J director | Feb 10, 2026 | Purchase | 20,000 | $1.49 | $29.8K | 0 | Form 4 ↗ |
Ellis Sean director | Feb 9, 2026 | Purchase | 18,000 | $1.24 | $22.3K | 178.1K | Form 4 ↗ |
OSTROV GERALD M director | Jan 1, 2026 | Award | 28,721 | — | — | 75.7K | Form 4 ↗ |
OSTROV GERALD M director | Jan 1, 2026 | Award | 33,505 | $1.94 | $65.0K | 33.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Entera Bio Ltd. (ENTX) is primarily owned by institutional investors, who hold approximately 18.6% of total shares outstanding. Company insiders own approximately 19.79%, while retail and public investors account for the remaining 61.56%.
The largest institutional shareholder of Entera Bio Ltd. is KNOLL CAPITAL MANAGEMENT, LLC, holding approximately 5.88 million shares — equal to 12.56% of outstanding shares — as of September 30, 2025.
A total of 22 institutional investors currently hold ENTX stock, with a combined institutional value of approximately $17,653,167 as of the most recent 13F filing period.
Frequently asked questions
ENTX ownershipEntera Bio Ltd. (ENTX) is primarily owned by institutional investors, who hold approximately 18.6% of shares. The largest shareholder is KNOLL CAPITAL MANAGEMENT, LLC with a 12.56% stake. Company insiders hold 19.79%. Data sourced from SEC Form 13F as of September 30, 2025.